Вирусы и эпидемии в истории мира. Прошлое, настоящее и будущее - Майкл Олдстоун

38. Kaufmann, D. E., D. G. Kavanagh, F. Pereyra, J. J. Zaunders, E. W. Mackey, T. Miura, S. Palmer, et al. “Upregulation of CTLA-4 by HIV-Specific CD4+ T Cells Correlates with Disease Progression and Defines a Reversible Immune Dysfunction.” Nature Immunology 8 (2007): 1246–54.

39. “Role of IL-10 in HIV Patients.” B. Walker Laboratory and A. McMichael Laboratory, unpublished results, personal communications 2007.

40. Andrabi, R., J. N. Bhiman, and D. R. Burton. “Strategies for a Multi-Stage Neutralizing Antibody-Based HIV Vaccine.” Current Opinion in Immunology 53 (2018): 143–51.

41. Burton, D. R., and L. Hangartner. “Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.” Annual Review of Immunology 34 (2016): 635–59.

42. Walker, L. M., and D. R. Burton. “Rational Antibody-Based HIV-1 Vaccine Design: Current Approaches and Future Directions.” Current Opinion in Immunology 22 (2010): 358–66.

43. Borrow, P., H. Lewicki, B. H. Hahn, G. M. Shaw, and M. B. Oldstone. “Virus-Specific CD8+ Cytotoxic T-Lymphocyte Activity Associated with Control of Viremia in Primary Human Immunodeficiency Virus Type 1 Infection.” Journal of Virology 68 (1994): 6103–10.

44. Walker, B. D., S. Chakrabati, B. Moss, T. J. Paradis, T. Flynn, A. G. Durno, R. S. Blumberg, J. C. Kaplan, M. S. Hirsch, and R. T. Schooley. “HIV Specific Cytotoxic T Lymphocytes in Seropositive Individuals.” Nature 328 (1987): 345–48.

45. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, and B. H. Hahn. “Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection.” Science 373 (1995): 117–22.

46. Fauci, A. “AIDS: Newer Concepts in the Immunopathogenic Mechanism of Human Immunodeficiency Virus Disease.” Proceedings of the Association of American Physicians 107 (1995): 1–7.

47. Chun, T. W., J. S. Justement, P. Pandya, C. W. Hallahan, M. McLaughlin, S. Liu, L. A. Ehler, C. Kovacs, and A. S. Fauci. “Relationship Between the Size of the Human Immunodeficiency Virus Type 1 (HIV-1) Reservoir in Peripheral Blood CD4+ T Cells and CD4+:CD8+ T Cell Ratios in Aviremic HIV-1-Infected Individuals Receiving Long-Term Highly Active Antiretroviral Therapy.” Journal of Infectious Diseases 185 (2002): 1672–76.

48. Chun, T. W., D. C. Nickle, J. S. Justement, J. H. Meyers, G. Roby, C. W. Hallahan, S. Kottilil, et al. “Persistence of HIV in Gut-Associated Lymphoid Tissue Despite Long-Term Antiretroviral Therapy.” Journal of Infectious Diseases 197 (2008): 714–20.

49. Guadalupe, M., E. Reay, S. Sankaran, T. Prindiville, J. Flamm, A. McNeil, and S. Dandekar. “Severe CD4+ T– Cell Depletion in Gut Lymphoid Tissue During Primary Human Immunodeficiency Virus Type 1 Infection and Substantial Delay in Restoration Following Highly Active Antiretroviral Therapy.” Journal of Virology 77 (2003): 11708–17.

50. Wiley, C., R. D. Schrier, J. A. Nelson, P. W. Lampert, and M. B. Oldstone. “Cellular Localization of Human Immunodeficiency Virus Infection Within the Brains of Acquired Immunodeficiency Syndrome Patients.” Proceedings of the National Academy of Sciences USA 83 (1986): 7089–93.

51. Moses, A. V., and J. A. Nelson. “HIV Infection of Human Brain Capillary Endothelial Cells – Implications for AIDS Dementia.” Advances in Neuroimmunology 4 (1994): 239–47.

52. Pierson, T., J. McArthur, and R. F. Siliciano. “Reservoirs for HIV-1: Mechanisms for Viral Persistence in the Presence of Antiviral Immune Responses and Antiretroviral Therapy.” Annual Review of Immunology 18 (2000): 665–708.

53. Le Gall, S., L. Erdtmann, S. Benichou, C. Berlioz-Torrent, L. Liu, R. Benarous, J. M. Heard, and O. Schwartz. “Nef Interacts with the Mu Subunit of Clathrin Adaptor Complexes and Reveals a Cryptic Sorting Signal in MHC 1 Molecules.” Immunity 8 (1998): 483–95.

54. Stumptner-Cuvelette, P., S. Morchoisne, M. Dugast, S. Le Gall, G. Raposo,O. Schwartz, and P. Benaroch. “HIV-1 Nef Impairs MHC Class II Antigen Presentation and Surface Expression.” Proceedings of the National Academy of Sciences USA 98 (2001): 12144–49.

55. Yang, O. O., P. T. Nguyen, S. A. Kalams, T. Dorfman, H. G. Göttlinger, S. Stewart, I. S. Chen, S. Threlkeld, and B. D. Walker. “Nef-Mediated Resistance of Human Immunodeficiency Virus Type 1 to Antiviral Cytotoxic T Lymphocytes.” Journal of Virology 76 (2002): 1626–31.

56. Wyatt, R., P. D. Kwong, E. Desjardins, R. W. Sweet, J. Robinson, W. A. Hendrickson, and J. G. Sodroski. “The Antigenic Structure of the HIV gp120 Envelope Glycoprotein.” Nature 393 (1998): 705–11.

57. Kwong, P. D., R. Wyatt, S. Majeed, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson. “Structures of HIV-1 gp120 Envelope Glycoproteins from Laboratory-Adapted and Primary Isolates.” Structure 8 (2000): 1329–39.

58. Haase, A. T., E. F. Retzel, and K. A. Staskus. “Amplification and Detection of Lentiviral DNA Inside Cells.” Proceedings of the National Academy of Sciences USA 87 (1990): 4971–75.

59. Harper, M. E., L. M. Marselle, R. C. Gallo, and F. Wong-Staal. “Detection of Lymphocytes Expressing Human T-Lymphocyte Virus Type III in Lymph Nodes and Peripheral Blood from Infected Individuals by In Situ Hybridization.” Proceedings of the National Academy of Sciences USA 83 (1986): 772–76.

60. Chun, T. W., and A. S. Fauci. “Latent Reservoirs of HIV: Obstacles to the Eradication of Virus.” Proceedings of the National Academy of Sciences USA 96 (1999): 10958–61.

61. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, et al. “Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy.” Science 278 (1997): 1295–1300.

62. Yarchoan, R. “HIV and KSHV-Related Cancers: Diseases at the Crossroads of Virology, Immunology, and Cell Biology.” Microbe 10 (2015): 157–62.

63. McFadyean, J., and F. Hobday. “Note on the Experimental Transmission of Warts in the Dog.” Journal of Comparative Pathology and Therapeutics 11 (1898): 341–44.

64. Zur Hausen, H. “Human Papillomaviruses and Their Possible Role in Squamous Cell Carcinomas.” Current Topics in Microbiology and Immunology 78 (1977): 1–30.

65. Lowy, D. R., and J. T. Schiller. “Prophylactic Human Papillomavirus Vaccines.” Journal of Clinical Investigation 116 (2006): 1167–73.

66. Frazer, I. H. “Prevention of Cervical Cancer Through Papillomavirus Vaccination.” Nature Reviews Immunology 4 (2004): 46–54.

67. Loeffler, F., and P. Frosch. “Berichte der Kommission zur Erforschung der Maul und Klauenseuche bei dem Institut Fur Infektionskrankheiten in Berlin.” Zentralblatt für Bakteriologie Parasitenkunde und Infektionskrankheiten I. 23 (1898): 371.